BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

Aug 30 2010

BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday, September 10, as part of the 7:00 - 9:00 AM podium presentation session.

BDSI previously announced positive top-line results from the study which showed that BEMA Buprenorphine demonstrated a statistically significant improvement compared to placebo in the primary efficacy endpoint, SPID-8 (sum of pain intensity differences at 8 hours; baseline observation carried forward analysis).

In addition, data will be presented which looked at a subset of patients with severe pain, where the analgesic efficacy of BEMA Buprenorphine was more profound.